Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed Adult AMLRefractory AML
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT06007911
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
- Conditions
- Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis
- Interventions
- Drug: 0.9% Chloride Injection Sodium
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Institute of Psychiatry and Neurology, Warsaw
- Target Recruit Count
- 188
- Registration Number
- NCT05961644
- Locations
- 🇵🇱
Institute of Psychiatry and Neurology, Warsaw, Mazowieckie, Poland
Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia, Adult
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT05906914
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Pontificia Universidade Católica do Rio Grande do Sul
- Target Recruit Count
- 10
- Registration Number
- NCT05902429
- Locations
- 🇧🇷
Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 360
- Registration Number
- NCT05797740
- Locations
- 🇬🇷
General Miliary Hospital of Athens "401", Athens, Greece
🇵🇹Centro Hospitalar Lisboa Norte Hospital de Santa Maria, Lisboa, Portugal
🇵🇹Centro Hospitalar Universitário Lisboa Central - Hospital dos Capuchos, Lisbon, Portugal
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 98
- Registration Number
- NCT05766514
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 32
- Registration Number
- NCT05578378
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
ChiCGB vs BEAM in High-risk or R/R Lymphomas
- Conditions
- Lymphoma, Large B-Cell, DiffuseLymphoma, T-Cell
- Interventions
- Procedure: Autologous hematopoietic stem cell transplant
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 306
- Registration Number
- NCT05466318
- Locations
- 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳West China Hospital, Sichuan University, Chendu, Sichuan, China
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- Conditions
- Myelodysplastic SyndromesMyeloproliferative Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05365035
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Ayman H Qasrawi
- Registration Number
- NCT05330377
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.